Immunomodulator is a chemical agent employed to regulate or normalize the immune system of the human body. Immunomodulators can offer an effective treatment for inflammatory bowel disease (IBD), particularly its types: ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, they are widely used in organ transplantations and in the treatment of autoimmune diseases. Sometimes, steroids are prescribed to be used with immunomodulators to accelerate the effect of immunomodulators Market.
The global Immunomodulators Market is driven by the growing prevalence of autoimmune diseases, rising cases of organ transplantation, increasing prevalence of inflammatory bowel disease, high rates of diagnosis and treatment of the aforementioned disorders, growing awareness about IBD and autoimmune disorders, competition between key players and local players, and high availability of immunomodulators across the world. Remarkable investments in R&D and technological advancements are projected to propel the global immunomodulators market during the forecast period. On the other hand, the global immunomodulators market is likely to face challenges from side-effects (for example, pain, inflammation, hypertension, epilepsy, headache, etc.) of immunomodulators and stringent regulatory policies regarding immunomodulators.
Based on application, the global immunomodulators market can be segmented into human and veterinary. According to the Cancer Investigation, immunomodulators have exhibited strong efficacy in the treatment of cancer and AIDS. Furthermore, according to a study conducted by the International Journal of Oral Health & Medical Research, immunomodulators are effective options for the treatment of oral diseases. In terms of disease type, the global immunomodulators market can be segmented into inflammatory bowel disease (IBD), autoimmune diseases, organ transplantations, cancer, and others (AIDS, oral diseases, etc.). Based on drug type, immunomodulators market has been divided into immuno-suppressants and immuno-stimulants. In terms of route of administration, the global immunomodulators market can be segmented into oral, parenteral, and others. Based on distribution channel, immunomodulators market can be categorized into hospital pharmacies, retail pharmacies & drugs stores, and others.
Request to View Brochure of Report -
Geographically, the global immunomodulators market has been classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to Centers for Disease Control & Prevention (CDC), around 0.24% and 0.29% of the people in the U.S. suffered from Crohn’s disease and ulcerative colitis respectively, in 2016. On the other hand, the estimated rate of prevalence of Crohn’s disease and ulcerative colitis stood at 0.0015%–0.21% and 0.0024%–0.294% respectively, in 2016, representing high prevalence of the two diseases in Nordic countries and the U.K.
Comments
Post a Comment